

(B) Performance Scenarios

The figures shown include all the costs of the Product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back. **What you will get from this product depends on future market performance.**

Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the Product / a suitable benchmark over the last 12 years. Markets could develop very differently in the future.

The stress scenario shows what you might get back in extreme market circumstances.

Recommended holding period:		7 years	
Example Investment:		JPY 1,000,000	
Scenarios		If you exit after 1 year	If you exit after 7 years (Recommended holding period)
Stress scenario	What you might get back after costs Average return each year	JPY 117,443 -88.3%	JPY 31,291 -39.0%
This type of scenario occurred for an investment UBS (Lux) Digital Health Equity Fund EB JPY between 02.2021-10.2024.			
Unfavourable scenario	What you might get back after costs Average return each year	JPY 596,902 -40.3%	JPY 621,461 -6.6%
This type of scenario occurred for an investment composite benchmark between 12.2016-12.2023.			
Moderate scenario	What you might get back after costs Average return each year	JPY 1,120,743 12.1%	JPY 2,279,187 12.5%
This type of scenario occurred for an investment composite benchmark between 04.2014-04.2021.			
Favourable scenario	What you might get back after costs Average return each year	JPY 1,922,217 92.2%	JPY 3,685,371 20.5%

What happens if UBS Asset Management (Europe) S.A. is unable to pay out?

The investor of this Product will not face financial loss due to the default of UBS Asset Management (Europe) S.A., as the Sub-fund is considered to be a separate entity with segregated assets.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Cost over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario
- JPY 1,000,000 is invested

	If you exit after 1 year	If you exit after 7 years (Recommended holding period)
Total costs	JPY 41,025	JPY 115,868
Annual cost impact (*)	4.1%	1.6%

(*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 14.1% before costs and 12.5% after costs.

Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	3.0% of the value of your investment when entering.	JPY 30,000
Exit costs	0.0% of the value of your investment before it is paid out to you.	JPY 0
Ongoing costs taken each year		
Management fees and other administrative or operating costs	1.1% of the value of your investment per year.	JPY 10,777
Transaction costs	0.0% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	JPY 248
Incidental costs taken under specific conditions		
Performance fees	There is no performance fee for this product.	n/a

How long should I hold it and can I take money out early?

Recommended holding period: 7 years

The recommended holding period is calculated based on the Summary Risk Indicator presented above. According to the investment objective as described above, the Product is designed for long-term investment. The Product is an open-ended Product. The investor can sell their investment on a daily (on business days) basis. No redemption fees or penalties will be charged at the level of the Product.

How can I complain?

If you have a complaint about the product, the producer of the product or the person who recommended or sold you the product, please contact your customer service representative or contact us at www.ubs.com/ame-regulatorydisclosures.

Other relevant information

This Key Information Document does not contain all information relating to this Product. Further information about CS Investment Funds 2, its prospectus and its latest annual and semi-annual report, the current Product prices, may be obtained free of charge, in English language, from UBS Asset Management (Europe) S.A., the appointed distributors or online at www.ubs.com/ame. There you can also find information on past performance from the last 2 years.

The calculations of previous performance scenarios, updated monthly, can be found at www.credit-suisse.com/fundsearch.

The information contained in this Key Information Document does not constitute a recommendation to buy or sell the Product and is no substitute for individual consultation with the investor's bank or advisor. Any updated version of this Key Information Document will be published on: www.ubs.com/ame.

Until 20th October 2024 the custodian of this Product is: Credit Suisse (Luxembourg) S.A., Luxembourg.

From 21st October 2024 the custodian of this Product is: UBS Europe SE, Luxembourg Branch.

Information for investors in Switzerland

Representative in Switzerland: UBS Fund Management (Switzerland) AG, Aeschenvorstadt 1, CH-4051 Basel

Paying agent in Switzerland: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich

Investors may obtain the Prospectus, the Key Information Document, a copy of the Articles of Incorporation as well as annual and semi-annual reports free of charge from the Representative in Switzerland.